- Home
- TVRD vs RNAC Comparison
TVRD vs RNAC Comparison
Compare TVRD & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- RNAC
- Stock Information
- Founded
- TVRD 2017
- RNAC 2007
- Country
- TVRD United States
- RNAC United States
- Employees
- TVRD N/A
- RNAC N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- TVRD Health Care
- RNAC Health Care
- Exchange
- TVRD Nasdaq
- RNAC Nasdaq
- Market Cap
- TVRD 246.5M
- RNAC 276.3M
- IPO Year
- TVRD N/A
- RNAC 2016
- Fundamental
- Price
- TVRD $33.88
- RNAC $9.68
- Analyst Decision
- TVRD Strong Buy
- RNAC Strong Buy
- Analyst Count
- TVRD 5
- RNAC 4
- Target Price
- TVRD $59.20
- RNAC $40.00
- AVG Volume (30 Days)
- TVRD 22.1K
- RNAC 51.1K
- Earning Date
- TVRD 08-14-2025
- RNAC 11-06-2025
- Dividend Yield
- TVRD N/A
- RNAC N/A
- EPS Growth
- TVRD N/A
- RNAC N/A
- EPS
- TVRD N/A
- RNAC N/A
- Revenue
- TVRD N/A
- RNAC $1,026,000.00
- Revenue This Year
- TVRD N/A
- RNAC N/A
- Revenue Next Year
- TVRD N/A
- RNAC N/A
- P/E Ratio
- TVRD N/A
- RNAC N/A
- Revenue Growth
- TVRD N/A
- RNAC N/A
- 52 Week Low
- TVRD $8.13
- RNAC $8.46
- 52 Week High
- TVRD $36.71
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- TVRD 66.16
- RNAC 37.49
- Support Level
- TVRD $29.33
- RNAC $9.73
- Resistance Level
- TVRD $31.88
- RNAC $10.83
- Average True Range (ATR)
- TVRD 2.09
- RNAC 0.51
- MACD
- TVRD 0.49
- RNAC -0.03
- Stochastic Oscillator
- TVRD 69.21
- RNAC 7.08
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.